Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Hew

Showing results (151-160 of 183) with videos related to

Pageof 19
Sort By:
Respiratory Medicine|September 5, 2025
Mepolizumab treatment and reduced oral corticosteroid exposure improves symptoms of depression and anxiety in severe eosinophilic asthma: data from the Australian Mepolizumab RegistryErin S Harvey, Yuto Hamada, Sarah A Hiles, et al.
The Journal of Allergy and Clinical Immunology|February 13, 2007
Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research ProgramWendy C Moore, Eugene R Bleecker, Douglas Curran-Everett, et al.
Internal Medicine Journal|February 28, 2020
Severe asthma assessment, management and the organisation of care in Australia and New Zealand: expert forum roundtable meetingsSteven Maltby, Vanessa M McDonald, John W Upham, et al.
Chest|December 1, 2019
Characterization of Severe Asthma Worldwide: Data From the International Severe Asthma RegistryEileen Wang, Michael E Wechsler, Trung N Tran, et al.
Allergy|August 26, 2023
Biologics (mepolizumab and omalizumab) induced remission in severe asthma patientsDennis Thomas, Vanessa M McDonald, Sean Stevens, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 5, 2021
Mepolizumab and Oral Corticosteroid Stewardship: Data from the Australian Mepolizumab RegistryDennis Thomas, Erin S Harvey, Vanessa M McDonald, et al.
The Journal of Allergy and Clinical Immunology. in Practice|September 5, 2018
Development of the International Severe Asthma Registry (ISAR): A Modified Delphi StudyLakmini Bulathsinhala, Nevaashni Eleangovan, Liam G Heaney, et al.
Respirology (Carlton, Vic.)|September 20, 2018
Treatable traits can be identified in a severe asthma registry and predict future exacerbationsVanessa M McDonald, Sarah A Hiles, Krystelle Godbout, et al.
Journal of Asthma and Allergy|January 20, 2022
Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE StudyAndrew N Menzies-Gow, Claire McBrien, Bindhu Unni, et al.
Chest|January 26, 2026
Interactive Pathways of Key Prognostic Factors in Severe Asthma: A Bayesian Network Comparison of Clinical Trials & Real-World DataChandra Prakash Yadav, Laura Huey Mien Lim, David Price, et al.
Pageof 19

Showing results (151-160 of 183) with videos related to

Sort By:
Pageof 19
Respiratory Medicine|September 5, 2025
Mepolizumab treatment and reduced oral corticosteroid exposure improves symptoms of depression and anxiety in severe eosinophilic asthma: data from the Australian Mepolizumab RegistryErin S Harvey, Yuto Hamada, Sarah A Hiles, et al.
The Journal of Allergy and Clinical Immunology|February 13, 2007
Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research ProgramWendy C Moore, Eugene R Bleecker, Douglas Curran-Everett, et al.
Internal Medicine Journal|February 28, 2020
Severe asthma assessment, management and the organisation of care in Australia and New Zealand: expert forum roundtable meetingsSteven Maltby, Vanessa M McDonald, John W Upham, et al.
Chest|December 1, 2019
Characterization of Severe Asthma Worldwide: Data From the International Severe Asthma RegistryEileen Wang, Michael E Wechsler, Trung N Tran, et al.
Allergy|August 26, 2023
Biologics (mepolizumab and omalizumab) induced remission in severe asthma patientsDennis Thomas, Vanessa M McDonald, Sean Stevens, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 5, 2021
Mepolizumab and Oral Corticosteroid Stewardship: Data from the Australian Mepolizumab RegistryDennis Thomas, Erin S Harvey, Vanessa M McDonald, et al.
The Journal of Allergy and Clinical Immunology. in Practice|September 5, 2018
Development of the International Severe Asthma Registry (ISAR): A Modified Delphi StudyLakmini Bulathsinhala, Nevaashni Eleangovan, Liam G Heaney, et al.
Respirology (Carlton, Vic.)|September 20, 2018
Treatable traits can be identified in a severe asthma registry and predict future exacerbationsVanessa M McDonald, Sarah A Hiles, Krystelle Godbout, et al.
Journal of Asthma and Allergy|January 20, 2022
Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE StudyAndrew N Menzies-Gow, Claire McBrien, Bindhu Unni, et al.
Chest|January 26, 2026
Interactive Pathways of Key Prognostic Factors in Severe Asthma: A Bayesian Network Comparison of Clinical Trials & Real-World DataChandra Prakash Yadav, Laura Huey Mien Lim, David Price, et al.
Pageof 19